Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Rosiglitazone use and associated adverse event rates in Canada between 2004 and 2010.

Rawson NS, Terres JA.

BMC Res Notes. 2013 Mar 5;6:82. doi: 10.1186/1756-0500-6-82.

2.

Rosiglitazone use and associated adverse event rates in Canada: an updated analysis.

Iczkovitz S, Dhalla D, Terres JA.

BMC Res Notes. 2015 Sep 29;8:505. doi: 10.1186/s13104-015-1448-6.

3.

New use of rosiglitazone decreased following publication of a meta-analysis suggesting harm.

Shah BR, Juurlink DN, Austin PC, Mamdani MM.

Diabet Med. 2008 Jul;25(7):871-4. doi: 10.1111/j.1464-5491.2008.02462.x.

PMID:
18644075
4.

The rise and fall of the thiazolidinediones: impact of clinical evidence publication and formulary change on the prescription incidence of thiazolidinediones.

Hashim S, Gomes T, Juurlink D, Hellings C, Mamdani M.

J Popul Ther Clin Pharmacol. 2013;20(3):e238-42. Epub 2013 Sep 6.

5.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
6.
7.

Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning.

Hall GC, Smith HT, Curtis B, McMahon AD.

Int J Clin Pract. 2011 May;65(5):586-91. doi: 10.1111/j.1742-1241.2011.02648.x.

PMID:
21489082
8.

Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.

Norwood P, Liutkus JF, Haber H, Pintilei E, Boardman MK, Trautmann ME.

Clin Ther. 2012 Oct;34(10):2082-90. doi: 10.1016/j.clinthera.2012.09.007. Epub 2012 Sep 29.

PMID:
23031623
9.

Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.

Ruiter R, Visser LE, van Herk-Sukel MP, Geelhoed-Duijvestijn PH, de Bie S, Straus SM, Mol PG, Romio SA, Herings RM, Stricker BH.

Drug Saf. 2012 Jun 1;35(6):471-80. doi: 10.2165/11596950-000000000-00000.

PMID:
22540371
10.

Thiazolidinediones and the influence of media adverse reporting on prescribing attitudes in practice (TZD-IMPACT) study.

George J, Hannah S 5th, Lang CC.

Cardiovasc Ther. 2009 Summer;27(2):83-8. doi: 10.1111/j.1755-5922.2009.00083.x.

PMID:
19426244
11.

Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings.

Jain R, Mullins CD, Lee H, Wong W.

Res Social Adm Pharm. 2012 Jan-Feb;8(1):47-59. doi: 10.1016/j.sapharm.2010.12.003. Epub 2011 Jul 6.

PMID:
21733760
12.

Case series of liver failure associated with rosiglitazone and pioglitazone.

Floyd JS, Barbehenn E, Lurie P, Wolfe SM.

Pharmacoepidemiol Drug Saf. 2009 Dec;18(12):1238-43. doi: 10.1002/pds.1804.

PMID:
19623674
13.

Cardiovascular risk of rosiglitazone: another perspective.

Waksman JC.

J Pharm Pharmacol. 2008 Dec;60(12):1573-82. doi: 10.1211/jpp.60.12.0002. Review.

PMID:
19000361
14.

Study of natural health product adverse reactions (SONAR): active surveillance of adverse events following concurrent natural health product and prescription drug use in community pharmacies.

Vohra S, Cvijovic K, Boon H, Foster BC, Jaeger W, LeGatt D, Cembrowski G, Murty M, Tsuyuki RT, Barnes J, Charrois TL, Arnason JT, Necyk C, Ware M, Rosychuk RJ.

PLoS One. 2012;7(9):e45196. doi: 10.1371/journal.pone.0045196. Epub 2012 Sep 28.

16.

Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.

Dahabreh IJ, Economopoulos K.

Clin Trials. 2008;5(2):116-20. doi: 10.1177/1740774508090212. Erratum in: Clin Trials. 2008;5(5):559. Economopoulos, K [added].

PMID:
18375649
17.

A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.

Cobitz A, Zambanini A, Sowell M, Heise M, Louridas B, McMorn S, Semigran M, Koch G.

Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):769-81. doi: 10.1002/pds.1615.

PMID:
18613278
18.

Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review.

Wang AT, McCoy CP, Murad MH, Montori VM.

BMJ. 2010 Mar 18;340:c1344. doi: 10.1136/bmj.c1344. Review.

19.

Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert.

Hurren KM, Taylor TN, Jaber LA.

Diabetes Res Clin Pract. 2011 Jul;93(1):49-55. doi: 10.1016/j.diabres.2011.02.035. Epub 2011 Mar 25.

PMID:
21440324
20.

Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records.

Brownstein JS, Murphy SN, Goldfine AB, Grant RW, Sordo M, Gainer V, Colecchi JA, Dubey A, Nathan DM, Glaser JP, Kohane IS.

Diabetes Care. 2010 Mar;33(3):526-31. doi: 10.2337/dc09-1506. Epub 2009 Dec 15.

Items per page

Supplemental Content

Write to the Help Desk